Ultragenyx EVP Karah Herdman Parschauer Sells Shares

EVP and Chief Legal Officer Karah Herdman Parschauer sold 1,899 shares of Ultragenyx.

Written by EarningsIQ · Published Jun 15, 2026, 7:01 PM EDT · Updated Jun 16, 2026, 2:01 PM EDT

Key Points

Karah Herdman Parschauer, EVP at Ultragenyx, sold 1,899 shares valued at $46,753 on June 15, 2026.
Ultragenyx Pharmaceutical Inc. trades near $24.35 with a market cap of $2.40 billion and a forward P/E of 25.23.
Cantor Fitzgerald maintained a 'buy' rating with a $96 target, while Goldman Sachs downgraded to 'hold' with a $25 target.

On June 15, 2026, Karah Herdman Parschauer, the Executive Vice President and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE), sold 1,899 shares of the company. This transaction was valued at $46,753, with an average selling price of $24.62 per share. The sale was part of a pre-planned trading strategy under Rule 10b5-1.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

Karah Herdman Parschauer's recent sale isn't the only insider activity at Ultragenyx. On the same day, Sanders Corazon sold 2,000 shares at $25.05 per share. Earlier, on June 1, Howard Horn, the Chief Financial Officer, sold 4,653 shares at an average price of $23.77, also under a pre-planned trading plan. Additionally, Shehnaaz Suliman sold shares on May 18, while buying shares on May 14, alongside Amrit Ray.

Other Institutional Activity in Ultragenyx

Several institutional investors have also adjusted their holdings in Ultragenyx. BlackRock, Inc. grew its holdings by 668,044 shares, ending with 7,299,598 shares worth about $152.9 million. State Street Corp increased its stake by 718,395 shares to a total of 5,021,441 shares valued at approximately $105.2 million. Meanwhile, AQR Capital Management LLC made a significant addition of 3,217,527 shares, bringing its total to 4,578,024 shares valued at $95.9 million.

Ultragenyx Stock Snapshot

Shares of Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) recently traded near $24.35. The company has a market capitalization of approximately $2.40 billion and a forward P/E ratio of 25.23. With a beta of 0.378, the stock has seen a 52-week low of $18.29 and a high of $42.37. Its 50-day moving average is $24.06, while the 200-day moving average is $27.12.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Ultragenyx. On May 21, 2026, Cantor Fitzgerald maintained a 'buy' rating with a target price of $96. Guggenheim and Barclays both set target prices at $43, maintaining their 'buy' ratings earlier in May. Meanwhile, Goldman Sachs recently downgraded the stock to 'hold' with a target price of $25 on March 24.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biotechnology company based in Novato, California. It specializes in developing and commercializing treatments for rare and ultra-rare genetic diseases. The company's portfolio includes products like Crysvita, Mepsevii, Dojolvi, and Evkeeza, aimed at various genetic disorders. Ultragenyx is led by CEO Dr. Emil D. Kakkis and employs around 1,371 people.

Bottom Line

Insider transactions like those by Karah Herdman Parschauer can provide insights into the activities of company executives. Investors often track these moves as part of their analysis. However, it's important to remember that such filings reflect past actions and may not indicate future plans.